OSCR — Stock Film
STOCK FILMSCENE 1/11OSCR · $30.77
Stock Expert AI presents
OSCR
Oscar Health, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Oscar Health, Inc. A quick introduction.

On the stock market since 2021, it operates in the world of health and science. It has 2,305 employees. Now — the numbers.

on the stock market since 2021
2,305 employees
$8B market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are growing, year after year.

Average growth of 57% a year over the last 4 years. Red columns mark years that ended in a loss.

$1.9B
2021
$4.1B
2022
$5.9B
2023
$9.2B
2024
$12B
2025
In the vault right now:
$0
DEBT: $430.1M
At this pace, that money lasts about 9 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
76
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
56
average

The cash pile is strong; debt and other items pull the grade toward the middle.

VALUATION
95
very strong

The price looks reasonable next to what the company earns.

GROWTH
36
weak

Clearly below the class average.

PRICE MOMENTUM
97
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
A strong cash pile8/10
Executives are buying stock10/10
Few are betting against it10/10
WEAK SPOTS
Thin profit on each sale3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 42% a year on average.

2
THE BRIGHT SIDE · 2/3
Sales are holding up

The company sells $11.7B a year; the problem isn’t sales — it’s costs running above that number.

3
THE BRIGHT SIDE · 3/3
Strong cash, light debt

There is $4.0B in the vault; even if every debt were paid off, $3.6B would remain.

1
THE RISKS · 1/3
Lost money last year

A loss of $443.2M against $11.7B in annual sales.

2
THE RISKS · 2/3
A wildly swinging price

This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.

3
THE RISKS · 3/3
The price sits above analysts’ target

The stock trades 21% above the average analyst price target.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, OSCR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: OSCR has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 22, 2026 · stockexpertai.com · Stock Film